BOLD (Boundless Bio) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Boundless Bio's net issuance of preferred for the three months ended in Mar. 2025 was $0.00 Mil. The number is 0, which means that Boundless Bio has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Boundless Bio's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Boundless Bio Net Issuance of Preferred Stock Historical Data

The historical data trend for Boundless Bio's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Net Issuance of Preferred Stock Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

105.32

99.67

Boundless Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Issuance of Preferred Stock	Get a 7-Day Free Trial							-	-	-	-	-

Boundless Bio Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Boundless Bio Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.